The BriefBrief · Intelligence, not news.
Download on the App Store Get it on Google Play

FDA rejects ivonescimab application

The U.S. Food and Drug Administration rejected the application for ivonescimab, a lung-cancer drug developed by China’s Akeso. Summit Therapeutics, which holds exclusive global development and commercialization rights, said the drug had not established “substantial evidence of effectiveness”; the FDA told the company it must show the drug helps patients live longer. Akeso shares fell as much as 31.8% Monday morning.

How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.

Know more. Read less.

The BriefBrief — updated continuously, every category, every day.
St. Petersburg approves Trails Crossing park plan
St. Petersburg Nov 16, 2026 at 12:20 AM ET
Air strike targets Hodeidah airport
Yemen Nov 16, 2026 at 12:06 AM ET
US and nine partners sign AI security pledge
United States Nov 16, 2026 at 12:05 AM ET
William and Kate host Earthshot ceremony in Mumbai
Prince William Nov 16, 2026 at 12:05 AM ET

Page 464 of 22954

Same format. Every time.

Continue reading — sign in or create a free account with